Neuroblastoma is the second deadliest cancer in children. This is largely attributed to high-risk neuroblastoma, which often has an abnormality known as MYCN amplification. Targeted therapies are newer cancer therapies that have already revolutionized how cancer is treated. Despite all the successes of targeted therapies, there have been no proven targeted therapy options for MYCN amplified neuroblastoma.